|Title:||Modulated TRPC1 expression predicts sensitivity of breast cancer to doxorubicin and magnetic field therapy: segue towards a precision medicine approach||Authors:||Tai, Yee Kit
Wing Chan, Karen Ka
Hua Fong, Charlene Hui
Yee Yap, Jasmine Lye
Yin, Jocelyn Naixin
Yip, Yun Sheng
Tan, Wei Ren
Fern Koh, Angele Pei
Tan, Nguan Soon
Chan, Ching Wan
Ju Huang, Ruby Yun
|Issue Date:||2021||Citation:||Tai, Yee Kit, Wing Chan, Karen Ka, Hua Fong, Charlene Hui, Ramanan, Sharanya, Yee Yap, Jasmine Lye, Yin, Jocelyn Naixin, Yip, Yun Sheng, Tan, Wei Ren, Fern Koh, Angele Pei, Tan, Nguan Soon, Chan, Ching Wan, Ju Huang, Ruby Yun, Franco-Obregón, Alfredo (2021). Modulated TRPC1 expression predicts sensitivity of breast cancer to doxorubicin and magnetic field therapy: segue towards a precision medicine approach. ScholarBank@NUS Repository. https://doi.org/10.1101/2021.04.30.442085||Abstract:||
Chemotherapy is the mainstream treatment modality for invasive breast cancer. Nonetheless, chemotherapy-associated adverse events can result in a patient terminating treatment. We show that transient receptor potential channel 1 (TRPC1) expression level predicts breast cancer sensitivity to doxorubicin (DOX) and pulsed electromagnetic field (PEMF) therapies.
The effects of PEMFs were examined with respect to:
Potential synergisms between DOX and PEMF therapies were examined in these model systems and under conditions of TRPC1 overexpression or silencing
PEMF exposure impaired the survival of MCF-7 cells, but not that of nonmalignant MCF10A breast cells. The effects of PEMF- and DOX-therapies synergized
The presented data supports a potential role of PEMF-therapy as an effective companion therapy to DOX-based chemotherapy for the treatment of breast cancers characterized by elevated TRPC1 expression levels.
|Appears in Collections:||Elements|
Show full item record
Files in This Item:
|Tai et al. 2021_Front_Oncol_27_Sept_21_C_upload ready_AFO_with Figures .pdf||Submitted version||7.94 MB||Adobe PDF|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.